3.05MMarket Cap-0.02P/E (TTM)
0.3952High0.3230Low8.74MVolume0.3455Open0.3493Pre Close3.08MTurnover97.55%Turnover Ratio0.00P/E (Static)8.99MShares14.748752wk High0.69P/B3.04MFloat Cap0.293552wk Low--Dividend TTM8.96MShs Float3341518.3292Historical High--Div YieldTTM20.67%Amplitude0.2930Historical Low0.3520Avg Price1Lot Size
Windtree Therapeutics Stock Forum
They did announce a meeting in February though to vote on another reverse split
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
Monday, 16th December at 8:00 am
WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Alexandre Mebazaa, MD, one of the...
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
Monday, 9th December at 8:00 am
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent ap...
Windtree Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price
https://www.moomoo.com/t/news/post/46681466/eMAmVfiVJf
No comment yet